Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations
DiscussionDrug-resistant epilepsy in children is associated with important costs to the healthcare system, and decision-makers require high-quality evidence on which to base reimbursement decisions. The results of this review will be useful to both decision-makers considering the decision problem of whether to reimburse cannabis-based products through public formularies and to analysts conducting studies in this area.Systematic review registrationPROSPERO no.:CRD42018099591.
Source: Systematic Reviews - Category: International Medicine & Public Health Source Type: research
More News: Brain | Children | Emergency Medicine | Epilepsy | Hospitals | International Medicine & Public Health | Neurology | Pediatrics | Study